Study Assesses Weekly Paclitaxel vs Every 3 Weeks for Ovarian Cancer

Share this content:
As compared with paclitaxel administered every 3 weeks, paclitaxel administered weekly did not prolong progression-free survival in ovarian cancer.
As compared with paclitaxel administered every 3 weeks, paclitaxel administered weekly did not prolong progression-free survival in ovarian cancer.

As compared with paclitaxel administered every 3 weeks, paclitaxel administered weekly did not prolong progression-free survival in patients with ovarian cancer, a study published in The New England Journal of Medicine has shown.1

A dose-dense schedule of paclitaxel given weekly plus carboplatin every 3 weeks or adding bevacizumab to paclitaxel and carboplatin administered every 3 weeks has demonstrated effectiveness in ovarian cancer. Therefore, researchers sought to evaluate whether dose-dense paclitaxel administered weekly and carboplatin would extend progression-free survival compared with paclitaxel and carboplatin given every 3 weeks among patients receiving or not receiving bevacizumab.

 

For the study, investigators enrolled 692 patients with ovarian cancer, of which 84% opted to receive immunotherapy. Participants were randomly assigned to receive paclitaxel 175 mg/m2 IV every 3 weeks or weekly paclitaxel 80 mg/m2 IV, plus carboplatin AUC 6 IV for 6 cycles.

In the intention-to-treat analysis, results showed that median progression-free survival was 14.7 months with weekly paclitaxel compared with 14.0 months with paclitaxel administered every 3 weeks (HR, 0.89; 95% CI, 0.74 - 1.06; P = .18).

Among patients who received bevacizumab, researchers found that weekly paclitaxel did not significantly improve progression-free survival vs paclitaxel given every 3 weeks (14.9 vs 14.7 months, respectively; HR, 0.99; 95% CI, 0.83 - 1.20; P = .60).

RELATED: Study Links Oral Contraceptive Use to Better Ovarian Cancer Outcomes

However, weekly paclitaxel was associated with a 3.9-month longer progression-free survival than paclitaxel administered every 3 weeks among patients who did not receive bevacizumab (14.2 vs 10.3 months; HR, 0.62; 95% CI, 0.40 - 0.95; P = .03).

In terms of safety, patients who received weekly paclitaxel experienced a higher incidence of grade 3 or 4 anemia and grade 2 to 4 sensory neuropathy than those who received it every 3 weeks, while patients who received paclitaxel every 3 weeks had a higher rate of grade 3 or 4 neutropenia.

Reference

  1. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016; 374:738-748.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters